How berberine changes gut bacteria

Berberine can change which bacteria live in the gut and which metabolites they produce. But what does that mean for health? Researchers are investigating whether these changes affect the gut barrier, bile acid metabolism and blood sugar regulation. How strongly the gut microbiome (the community of microorganisms living in the gut) responds to berberine, and whether a health benefit follows, cannot yet be reliably predicted for any individual. Some of the mechanisms described here come from experimental studies and animal models.

How berberine interferes with bacterial energy production

Berberine belongs to the quaternary ammonium alkaloids. These are nitrogen-containing compounds; berberine is extracted from goldenseal and barberry, among other plants. Its bright yellow color comes from its chemical isoquinoline structure. That structure also matters for how berberine affects energy production in gut bacteria: it can inhibit the enzyme ATP synthase and suppress the formation of NADH. ATP is the cell’s energy carrier, and NADH shuttles electrons during metabolic reactions. When these processes are disrupted, bacteria whose metabolism depends less on the affected enzymes gain an advantage. This creates selective pressure within the bacterial community.

After you take it, a large share of the berberine stays in the gut. Its oral bioavailability, meaning the fraction of a swallowed dose that reaches the general circulation, is reported at about 5%. A considerable part of each dose therefore sits in the gut lumen, the inner space of the intestine where the bacteria live. Gut microbes can use their enzymes to convert berberine into dihydroberberine, which the body absorbs more easily. Berberine’s poor absorption favors a local effect on the microorganisms. It does not, however, rule out concentrations in the body high enough to affect human mitochondria as well. These cell components are responsible for energy production.

Bacteria considered sensitive include those that rely heavily on oxidative phosphorylation for energy. In this process, ATP is made with the help of an electron transport chain. Among the groups described as sensitive are certain gram-negative bacteria that produce lipopolysaccharide (LPS). LPS is part of their outer membrane and can trigger inflammatory responses. If the relevant Enterobacteriaceae decline, fewer of these substances, known as endotoxins, might reach the bloodstream when the gut barrier is leaky. Changes in certain Clostridium species are also described. Clostridia, however, are not among the LPS-producing gram-negative bacteria, so their changes need to be considered separately.

Which bacteria berberine inhibits and what might follow

Berberine can shift the balance between different groups of bacteria in the gut. Declines have been described in certain groups linked to metabolic disorders or inflammation. Labeling entire bacterial groups as simply “beneficial” or “harmful” does only limited justice to their varied properties, though:

• Certain Clostridium species decrease, especially those involved in bile acid deconjugation. In this process, bacterial enzymes break bonds on the bile acids. Changes to this process could affect fat metabolism and the gut barrier (randomized controlled trial from 2020).
• Declines are also described for Enterobacteriaceae. This family includes opportunistic pathogens such as E. coli and Klebsiella, which can cause disease under certain conditions. The declines go along with lower LPS concentrations in the blood and lower markers of endotoxin exposure. That these values change together does not yet prove a causal link.
• Ruminococcus gnavus responds to berberine in varying ways. There are also findings that berberine strengthens the proteins that bind neighboring cells of the gut lining tightly together. These connections are called tight junctions. Such an effect could counteract the consequences of mucin breakdown. Mucins are components of the protective mucus layer in the gut.

How large these changes are depends on the dose. With continued use, they tend to develop over weeks rather than days. A suitable individual dose cannot yet be derived from this.

Less lipopolysaccharide and inflammation in the body

When gram-negative bacteria multiply or die off, LPS from their outer membrane can enter the gut lumen. If the gut barrier is more permeable, it can pass into the blood and trigger immune responses. This can contribute to chronic low-grade inflammation. Berberine could reduce the body’s endotoxin load in two ways: by reducing LPS-producing bacteria and by making the gut barrier more stable. This mechanism is discussed as a possible explanation for effects on insulin resistance, fatty liver and cardiovascular risk factors. Whether it also leads to fewer cases of cardiovascular disease cannot be inferred from the mechanism alone.

Bile acids and the FXR pathway

The liver produces bile acids and releases them into the gut to help digest fat. There, gut bacteria modify the bile acids before they are reabsorbed. Berberine can influence bacterial enzymes involved in deconjugation and in forming secondary bile acids. This can change the composition of the bile acid pool, meaning the full set of bile acids present. That in turn can affect farnesoid X receptor (FXR) signaling in the gut and liver. This receptor helps regulate glucose and cholesterol metabolism. Researchers are studying whether activating it contributes to better blood sugar regulation and less fat buildup in the liver.

Which potentially beneficial bacteria berberine might favor

When berberine inhibits certain groups of bacteria, growing conditions can improve for other species:

• Increases in Akkermansia muciniphila have been described with berberine. Higher levels of this bacterium are associated with a more stable gut barrier, better glucose tolerance and less body fat accumulation. Glucose tolerance describes how well the body handles an intake of glucose. A higher share of the bacterium alone, however, does not prove that these effects will occur in a given person.
• Faecalibacterium prausnitzii also increases in several of the studies described. This bacterium produces butyrate, a metabolite that could contribute to anti-inflammatory effects and changes in metabolism.
• Bifidobacterium species respond in varying ways. Diet before starting berberine probably plays a role here, especially fiber intake. These bacteria use fermentable food components as substrates, meaning the raw materials for their metabolism.

Prebiotic fibers are food components that certain gut microorganisms can use. Combined with berberine, they might more strongly promote the growth of bacteria that depend on such substrates. An established additional health benefit of the combination cannot yet be derived from this biological explanation.

How berberine changes the production of short-chain fatty acids

When gut bacteria ferment fiber, they produce short-chain fatty acids (SCFAs). The main ones are acetate, propionate and butyrate. They serve as an energy source for the cells of the colon lining, the colonocytes, and help regulate immune function. Through G protein-coupled receptors, they also influence metabolism throughout the body. These receptors relay signals from outside a cell to its interior. Berberine can change the makeup of the bacteria involved in this breakdown process, called fermentation. In doing so, it can also affect SCFA production.

Metabolic research pays particular attention to butyrate. One of its described mechanisms is activating AMP-activated protein kinase (AMPK) in muscle and liver, which can improve insulin sensitivity. AMPK is an enzyme that regulates a cell’s energy balance. Insulin sensitivity describes how well cells respond to the hormone insulin. Butyrate can also strengthen the tight connections between gut cells, reduce intestinal permeability and dampen inflammatory signaling in immune cells. Through processes like these, the microbiome could mediate part of berberine’s effects.

Higher propionate levels have also been described with berberine. This short-chain fatty acid influences appetite regulation and glucose production in the liver. It can also activate gluconeogenesis in the gut, meaning the production of new glucose. Via the gut-brain axis, the link between the gut and the brain, this process can relay satiety signals. That could explain reports of less hunger while taking berberine, which the substance’s direct effects alone do not account for. A reliable appetite-suppressing effect in humans has not been shown so far.

Why berberine does not work the same way in everyone

How the microbiome is composed before someone starts taking berberine probably helps determine how strongly berberine changes the gut bacteria. If levels of Akkermansia and Faecalibacterium are already high, both further changes and metabolic effects might stay small. With many LPS-producing Enterobacteriaceae and few butyrate producers, larger changes would be conceivable. Such baseline patterns do not yet allow a reliable prediction for any individual.

Diet also shapes the conditions under which berberine acts on the microbiome. Fiber-rich food supplies substrates for SCFA-producing bacteria, whose growth berberine might favor. On a low-fiber, high-fat diet, their growth may stay limited even while other bacteria decline. As a result, the microbiome’s makeup might shift in a less favorable direction.

Antibiotics taken before or during berberine use can weaken its microbial effects. Broad-spectrum antibiotics can sharply reduce both potentially harmful and beneficial bacteria. It can take months for the altered microbial community to recover. If berberine is taken right after a course of antibiotics, the expected metabolic effects might not appear: both the bacteria that are sensitive to berberine and the species whose growth it might favor may then be depleted or missing.

Genetic differences between bacterial strains

Strains of the same bacterial species can differ genetically. That is why not all strains of Akkermansia or Faecalibacterium respond the same way to berberine’s antimicrobial mechanisms. Some people might carry resistant strains that do not increase with berberine. Analyses that distinguish individual strains could help study these differences. That level of detail is not yet standard in commercial microbiome tests. Whether such a test can reliably predict who will benefit from berberine has not been established.

Gut transit time and contact with berberine

Gut transit time describes how long the gut contents take to pass through the intestine. With faster transit, berberine and gut bacteria are in contact for a shorter time, which could limit changes to the microbiome. Slower transit lengthens the contact, but might also encourage gastrointestinal side effects. These include diarrhea, which can itself alter the microbiome. Individual transit time could therefore matter in research on suitable doses. In everyday clinical practice, however, it is rarely measured. No established method has yet emerged for adjusting the berberine dose based on this value.

How the microbiome’s response can be studied

Microbiome analyses before and after taking berberine can capture whether the measured bacterial composition has changed. A test before starting records, for example, how abundant Akkermansia, Faecalibacterium, Enterobacteriaceae and Clostridium species are. A repeat analysis after 8 to 12 weeks can show changes in these groups. Whether this comes with a health benefit cannot be read from a higher share of a species considered favorable, or a lower share of another group, on its own.

SCFA levels in stool can offer further clues about whether the metabolic activity of the gut microbes has changed. Higher butyrate and propionate levels could fit with greater activity of fiber-fermenting bacteria. Unchanged or lower levels may suggest that an expected change did not happen. Stool concentrations, however, do not directly reflect either the total production of these substances or their effects in the body. So the values do not directly tell you whether the dose, timing or fiber intake should be changed.

Blood markers such as high-sensitivity C-reactive protein (hs-CRP), fasting glucose, fasting insulin and triglycerides can capture accompanying changes in inflammatory activity and metabolism. hs-CRP is a marker of inflammation; fasting glucose and fasting insulin describe the glucose and insulin concentrations in the fasted state. Triglycerides are a type of blood fat. If the gut bacteria change without any improvement in glucose and blood lipid values, the extent of insulin resistance, liver function or drug interactions, among other things, could play a role. Insulin resistance means that cells respond less to insulin. Blood values cannot, however, prove that an observed change was caused by the microbiome.

How possible metabolic effects can be measured

Studies of berberine’s possible metabolic effects measure fasting glucose, HbA1c, triglycerides, the TyG index and inflammation markers such as hs-CRP, among others. HbA1c describes the share of hemoglobin, the red blood pigment, that has glucose attached, and reflects blood sugar levels over a longer period. The TyG index is calculated from triglycerides and fasting glucose. It serves as an indirect sign of insulin resistance.

Measurements before starting berberine and again after 12 weeks show whether these values have changed. Combined with microbiome analyses, they make it possible to examine which bacterial groups and metabolites changed in parallel and whether metabolic effects occurred at the same time. The measurements do not capture every process, however, and do not prove a causal contribution from the gut bacteria. Nor can they reliably predict how well berberine will work for a particular person.

Frequently asked questions

Why does berberine affect gut bacteria when it is used as a supplement for metabolism?

Only a small share of the berberine you take reaches the general circulation: oral bioavailability is about 5%. A large part of each dose therefore initially stays in the gut lumen, where the gut bacteria live. There, berberine can act directly on the bacterial community even before it is absorbed, and inhibit certain bacteria. Changes to the microbiome are being studied as one of the routes by which berberine could influence glucose metabolism, inflammatory processes and the handling of fats. How large this contribution is compared with berberine’s direct effects cannot be determined with certainty from this.

Which bacteria are sensitive to berberine?

The groups described as sensitive include certain gram-negative, LPS-producing Enterobacteriaceae, such as E. coli and Klebsiella. Declines are also observed in certain Clostridium species involved in bile acid deconjugation. Clostridia, though, are not among the LPS-producing gram-negative bacteria. Reliable suppression of specific species in everyone has not been established so far.

One proposed mechanism is that berberine inhibits bacterial ATP synthase. This could matter mainly for bacteria whose energy production depends heavily on oxidative phosphorylation; it cannot be applied across the board to all the species named. When LPS-producing bacteria decline, LPS concentrations in the blood and markers of endotoxin exposure in the body can fall at the same time.

What is Akkermansia muciniphila, and why might an increase with berberine matter?

Akkermansia muciniphila lives in the gut’s mucus layer and takes part in processes that maintain the gut barrier. Higher levels are associated with better glucose tolerance, less body fat accumulation and less inflammation in the body. If berberine inhibits competing bacteria, that can improve growing conditions for Akkermansia.

Studies describe increases with berberine. These could explain part of its effects on insulin sensitivity and inflammation, in addition to direct AMPK activation. According to the findings cited, however, clinical studies in humans do not consistently show such an increase or a resulting health benefit.

How are short-chain fatty acids from gut bacteria connected to berberine’s metabolic effects?

Butyrate and propionate are produced when gut bacteria ferment fiber. Both are being studied as possible mediators of berberine’s metabolic effects. Butyrate can activate AMPK in muscle and liver tissue and so influence insulin sensitivity. It can also strengthen the tight connections between gut cells and reduce intestinal permeability. Propionate can activate glucose production in the gut, which relays satiety signals via the gut-brain axis.

If berberine favors bacteria that produce these fatty acids, it could trigger additional metabolic effects this way. Faecalibacterium prausnitzii matters here mainly as a butyrate producer. How much these mechanisms affect health in practice when someone takes berberine has not yet been shown.

Does diet affect how much berberine changes the microbiome?

Yes. Diet helps determine which substrates gut bacteria can use. Fiber-rich food supplies fermentable material for butyrate producers, whose growth berberine might favor. A low-fiber, high-fat diet can limit this growth, even while other bacterial groups decline. The microbiome’s overall response might be weaker.

Getting enough fiber alongside berberine could encourage more favorable and longer-lasting changes than berberine alone. This assumption is biologically plausible; an additional benefit in humans has not yet been demonstrated.

Why can two people on the same berberine dose respond very differently?

Several factors could explain why the microbiome changes differently. Its makeup before starting berberine is probably especially relevant: if levels of Akkermansia and Faecalibacterium are already high, further shifts might stay small. Genetic differences between bacterial strains also play a role. Different Akkermansia strains, for example, can vary in how sensitive they are to antimicrobial mechanisms.

Gut transit time helps determine how long berberine is in contact with the bacteria. Previous antibiotic treatment can also reduce precisely the groups that berberine acts on or whose growth it might favor. These factors offer possible explanations, but do not yet allow a reliable prediction for any individual.

How long does it take for berberine to produce measurable changes in gut bacteria?

Microbiome changes tend to develop and stabilize over weeks rather than days. For clinical studies of microbial composition, a period of 8 to 12 weeks is often described. Within this window, possible changes in potentially favorable and unfavorable bacterial groups can be captured.

Accompanying metabolic effects, for example on fasting glucose and triglycerides, can become visible after 4 to 12 weeks. To the extent that the microbiome mediates these effects, they arise from changes over time and are not an acute response to a single dose. These time frames describe possible observation periods; they guarantee neither a measurable change nor a benefit.

Which blood values can point to metabolic effects with berberine?

To assess possible metabolic effects, markers such as fasting glucose, fasting insulin, HbA1c, triglycerides and hs-CRP are used. A lower hs-CRP value can indicate less inflammatory activity in the body. It does not show, however, whether berberine has reduced the burden from LPS-producing bacteria.

Improvements in fasting insulin and triglycerides can fit with better insulin sensitivity and a change in the liver’s fat metabolism. Whether higher production of short-chain fatty acids or a lower endotoxin load is responsible cannot be inferred from these blood values alone.

References

• Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, Yang J, Chen L, Chen G, Qu S, Liang J, Qin L, Huang Q, Peng Y, Li Q, … Wang W (2020). Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications, 11(1), 5015. https://doi.org/10.1038/s41467-020-18414-8. PubMed.

• Dong C, Yu J, Yang Y, Zhang F, Su W, Fan Q, Wu C, Wu S (2021). Berberine, a potential prebiotic to indirectly promote Akkermansia growth through stimulating gut mucin secretion. Biomedicine & pharmacotherapy, 139, 111595. https://doi.org/10.1016/j.biopha.2021.111595. PubMed.

• Tian Y, Cai J, Gui W, Nichols RG, Koo I, Zhang J, Anitha M, Patterson AD (2019). Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation. Drug Metabolism and Disposition, 47(2), 86-93. https://doi.org/10.1124/dmd.118.083691. PubMed.

• Xu JH, Liu XZ, Pan W, Zou DJ (2017). Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Molecular Medicine Reports, 15(5), 2765-2787. https://doi.org/10.3892/mmr.2017.6321. PubMed.

• Gu L, Li N, Gong J, Li Q, Zhu W, Li J (2011). Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. The Journal of Infectious Diseases, 203(11), 1602-1612. https://doi.org/10.1093/infdis/jir147. PubMed.